Combo Products Face Costlier Process Under Europe’s New MDD – Alcon Exec
This article was originally published in The Gray Sheet
Executive Summary
The combination product policy outlined in the proposed revisions to Europe's Medical Devices Directive is emerging as a leading industry concern
You may also be interested in...
European Device Reclassifications Are Burdensome, Trade Groups Say
Comments from AdvaMed and its European counterpart Eucomed raise concerns about device reclassifications appearing in the revised Medical Devices Directive
MDD Revision Clarifies Existing Policies, Tightens Industry Loopholes
A draft revision of the European Medical Devices Directive would give manufacturers of implantable and Class III devices less leeway to avoid clinical evaluation requirements
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: